top of page



Mr. Gover has over twenty-five years of experience in leadership positions in the biotechnology industry in the UK and US. He was the founding CEO of GW Pharmaceuticals plc (GWPH), which was acquired by Jazz Pharmaceuticals plc (JAZZ) for $7.2 billion in May 2021. He currently serves on the Board of Xenon Pharmaceuticals (XENE). From 2018-2021, Mr. Gover served on the Board of Directors of the Biotechnology Innovation Organization (BIO).


Mr. Gover served as CEO and a Board Director of GW since the company’s inception in 1999. He raised private capital in the UK before listing GW on the London Stock Exchange in 2001 and subsequently led the company’s Initial Public Offering on Nasdaq in 2013. In total, he led equity financing rounds for GW which raised approximately $1.5 billion. GW is a world leader in cannabinoid science and successfully developed and commercialized Epidiolex, a first in class treatment in the field of childhood-onset epilepsy. Epidiolex represented a historic breakthrough as the first plant-derived cannabinoid medicine ever to be approved by FDA and is approved to treat seizures associated with Lennon-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex. Prior to this, in 2010, GW successfully obtained approval for Sativex in the field of multiple sclerosis in Europe.


Prior to joining GW, from 1995-1998, Mr. Gover was Head of Corporate Affairs at Ethical Holdings plc, a UK-based Nasdaq listed biotechnology company that developed medicines utilizing its proprietary drug delivery technologies. Mr. Gover holds an M.B.A. from the INSEAD business school in France and a BSc (Hons) from Bristol University, UK.

bottom of page